ONCO

Onconetix, Inc.
CAPPED RATING

Onconetix, Inc. (ONCO) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (F). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
B+
Factor Score 3.5 / 5.0
Growth
F
Factor Score 0.3 / 5.0
Profitability
C
Factor Score 2.5 / 5.0
Momentum
F
Factor Score 0.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.6
Rev Growth YoY -83.9%
Gross Margin 80.4%
Price Return 3M -57.6%
Price Return 12M -99.8%
Catalyst Signal 0.00
Market Cap $2.2M
TTM Revenue $645.8K
Price / Sales 3.3
ROE -105.2%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B+ (3.5) F (0.3) C (2.5) F (0.7) C+ (2.6) C- (1.9)
2026-11-07 B+ (3.5) F (0.2) C+ (2.5) D (1.5) C+ (2.7) C- (2.1)
2026-10-31 B+ (3.5) F (0.2) C (2.5) D (1.2) C+ (2.7) C- (2.0)
2026-10-24 B (3.5) F (0.2) C (2.5) D- (0.7) C+ (2.6) C- (1.9)
2026-10-17 B (3.5) F (0.2) C (2.5) D- (0.7) C+ (2.6) C- (1.9)
Page 1 of 4